Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Clinical spectrum of high-titre GAD65 antibodies.

Authors:
Adrian Budhram Elia Sechi Eoin P Flanagan Divyanshu Dubey Anastasia Zekeridou Shailee S Shah Avi Gadoth Elie Naddaf Andrew McKeon Sean J Pittock Nicholas L Zalewski

J Neurol Neurosurg Psychiatry 2021 Feb 9. Epub 2021 Feb 9.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA

Objective: To determine clinical manifestations, immunotherapy responsiveness and outcomes of glutamic acid decarboxylase-65 (GAD65) neurological autoimmunity.

Methods: We identified 323 Mayo Clinic patients with high-titre (>20 nmol/L in serum) GAD65 antibodies out of 380 514 submitted anti-GAD65 samples (2003-2018). Patients classified as having GAD65 neurological autoimmunity after chart review were analysed to determine disease manifestations, immunotherapy responsiveness and predictors of poor outcome (modified Rankin score >2).

Results: On review, 108 patients were classified as not having GAD65 neurological autoimmunity and 3 patients had no more likely alternative diagnoses but atypical presentations (hyperkinetic movement disorders). Of remaining 212 patients with GAD65 neurological autoimmunity, median age at symptom onset was 46 years (range: 5-83 years); 163/212 (77%) were female. Stiff-person spectrum disorders (SPSD) (N=71), cerebellar ataxia (N=55), epilepsy (N=35) and limbic encephalitis (N=7) could occur either in isolation or as part of an overlap syndrome (N=44), and were designated core manifestations. Cognitive impairment (N=38), myelopathy (N=23) and brainstem dysfunction (N=22) were only reported as co-occurring phenomena, and were designated secondary manifestations. Sustained response to immunotherapy ranged from 5/20 (25%) in epilepsy to 32/44 (73%) in SPSD (p=0.002). Complete immunotherapy response occurred in 2/142 (1%). Cerebellar ataxia and serum GAD65 antibody titre >500 nmol/L predicted poor outcome.

Interpretation: High-titre GAD65 antibodies were suggestive of, but not pathognomonic for GAD65 neurological autoimmunity, which has discrete core and secondary manifestations. SPSD was most likely to respond to immunotherapy, while epilepsy was least immunotherapy responsive. Complete immunotherapy response was rare. Serum GAD65 antibody titre >500 nmol/L and cerebellar ataxia predicted poor outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2020-325275DOI Listing
February 2021

Publication Analysis

Top Keywords

gad65 neurological
20
neurological autoimmunity
16
serum gad65
12
cerebellar ataxia
12
gad65 antibodies
12
gad65
10
immunotherapy responsiveness
8
antibody titre
8
poor outcome
8
patients classified
8
complete immunotherapy
8
immunotherapy response
8
manifestations immunotherapy
8
classified gad65
8
gad65 antibody
8
>500 nmol/l
8
secondary manifestations
8
predicted poor
8
high-titre gad65
8
titre >500
8

Keyword Occurance

Similar Publications

Longitudinal CSF Findings in Autoimmune Encephalitis-A Monocentric Cohort Study.

Authors:
Tobias Zrzavy Romana Höftberger Isabella Wimmer Thomas Berger Paulus Rommer Stefan Macher

Front Immunol 2021 22;12:646940. Epub 2021 Mar 22.

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Autoimmune encephalitis (AIE) poses a diagnostic challenge due to its heterogeneous clinical presentation, which overlaps with various neurological and psychiatric diseases. During the diagnostic work-up, cerebrospinal fluid (CSF) is routinely obtained, allowing for differential diagnostics as well as for the determination of antibody subclasses and specificities. In this monocentric cohort study, we describe initial and serial CSF findings of 33 patients diagnosed with antibody-associated AIE (LGI1 (n=8), NMDA (n=7), CASPR2 (n=3), IgLON5 (n=3), AMPAR (n=1), GAD65/67 (n=4), Yo (n=3), Ma-1/2 (n=2), CV2 (n=2)). Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity.

Authors:
Kelsey M Smith Nicholas L Zalewski Adrian Budhram Jeffrey W Britton Elson So Gregory D Cascino Anthony L Ritaccio Andrew McKeon Sean J Pittock Divyanshu Dubey

Epilepsia 2021 Mar 25. Epub 2021 Mar 25.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

The objective of this study was to describe serological association of musicogenic epilepsy and to evaluate clinical features and outcomes of seropositive cases. Through retrospective chart review, musicogenic epilepsy patients were identified. Among 16 musicogenic epilepsy patients, nine underwent autoantibody evaluations and all had high-titer glutamic acid decarboxylase 65-immunoglobulin G (GAD65-IgG; >20 nmol·L , serum, normal ≤ . Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Clinical spectrum of high-titre GAD65 antibodies.

Authors:
Adrian Budhram Elia Sechi Eoin P Flanagan Divyanshu Dubey Anastasia Zekeridou Shailee S Shah Avi Gadoth Elie Naddaf Andrew McKeon Sean J Pittock Nicholas L Zalewski

J Neurol Neurosurg Psychiatry 2021 Feb 9. Epub 2021 Feb 9.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA

Objective: To determine clinical manifestations, immunotherapy responsiveness and outcomes of glutamic acid decarboxylase-65 (GAD65) neurological autoimmunity.

Methods: We identified 323 Mayo Clinic patients with high-titre (>20 nmol/L in serum) GAD65 antibodies out of 380 514 submitted anti-GAD65 samples (2003-2018). Patients classified as having GAD65 neurological autoimmunity after chart review were analysed to determine disease manifestations, immunotherapy responsiveness and predictors of poor outcome (modified Rankin score >2). Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study.

Authors:
Sergio Muñiz-Castrillo Alberto Vogrig Clémentine Montagnac Bastien Joubert Marie Benaiteau Olivier Casez Hugo Chaumont Lucie Hopes Hélène-Marie Lanoiselée Vincent Navarro Benjamin Thomas Renata Ursu David Gonçalves Nicole Fabien François Ducray Cécile Julier Jérôme Honnorat

J Neurol 2021 Feb 5. Epub 2021 Feb 5.

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, 59 Boulevard Pinel, 69677, Bron Cedex, France.

The common co-occurrence of autoimmune systemic diseases in patients with neurological disorders and antibodies against glutamic acid decarboxylase 65 (GAD65) suggests a shared genetic predisposition to these disorders. However, the nature and frequency of familial aggregation of autoimmune diseases, which might also support this hypothesis, have been poorly investigated. Herein, an exploratory, interview-based study was conducted with the aim of describing the autoimmune diseases displayed by the relatives of GAD65 neurological patients, their frequency, kinship, and potential patterns of inheritance. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Clinical features of paediatric and adult autoimmune encephalitis: A multicenter sample.

Authors:
Annie Roliz Yash Shah Anne Morse Matthew Troester Rebecca Lynch Jacob Pickle Shefali Karkare Cristina Fernandez-Carbonell Sanjeev Kothare

Eur J Paediatr Neurol 2021 Jan 7;30:82-87. Epub 2021 Jan 7.

Division of Child Neurology, Department of Paediatrics, Cohen Children's Medical Center, 2001 Marcus Ave, Suite W290, New Hyde Park, NY, 11042, USA. Electronic address:

Background: Autoimmune encephalitis (AE) is a heterogeneous class of inflammatory diseases of the brain that can present with a wide spectrum of neuropsychiatric symptoms. Patients may be negative for CSF anti-neuronal antibodies, which can make the diagnosis of AE challenging. Distinguishing features between paediatric and adult patients with AE are not well characterized. Read More

View Article and Full-Text PDF
January 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap